Management of relapsing Plasmodium vivax malaria.
Management of relapsing Plasmodium vivax malaria.
复制标题
DOI：
10.1080/14787210.2016.1220304
复制
发表时间：
2016-10
影响因子：
5.7
通讯作者：
White NJ
中科院分区：
文献类型：
--
作者：
Chu CS;White NJ
导言：复发是间日疟原虫和卵形疟原虫感染的疾病和发病率的重要因素。为了最佳管理、控制和最终消灭间日疟原虫疟疾，需要伯氨喹预防复发（根治）。使用检索词“间日疟原虫”和“复发”对英文、法文、葡萄牙文和西班牙文出版物进行了审查。 覆盖的领域：导致复发的催眠虫可能在最初感染后数周或数月被激活。复发的发生率和时间模式因地域而异。复发来自寄生虫，与原发感染在遗传上相似或不同，这表明有些来自先前的感染。疟疾疾病本身可能会引发复发。伯氨喹是唯一广泛使用的根治性治疗方法。然而，它往往是不给，因为伯氨喹诱导溶血的风险不确定性时，G6 PD缺乏测试是不可用的。在东亚和大洋洲，伯氨喹根治的推荐剂量为0.5 mg碱/kg/天，其他地方为0.25 mg碱/kg/天。替代治疗方法正在调查中。 专家评论：间日疟原虫复发模式和氯喹敏感性的地理异质性，以及G6 PD缺乏症的流行病学意味着根治性治疗应该比现在更多。G6 PD测试应该广泛使用，以便伯氨喹可以更安全地使用。
Introduction: Relapses are important contributors to illness and morbidity in Plasmodium vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria. A review was conducted with publications in English, French, Portuguese and Spanish using the search terms ‘P. vivax’ and ‘relapse’. Areas covered: Hypnozoites causing relapses may be activated weeks or months after initial infection. Incidence and temporal patterns of relapse varies geographically. Relapses derive from parasites either genetically similar or different from the primary infection indicating that some derive from previous infections. Malaria illness itself may activate relapse. Primaquine is the only widely available treatment for radical cure. However, it is often not given because of uncertainty over the risks of primaquine induced haemolysis when G6PD deficiency testing is unavailable. Recommended dosing of primaquine for radical cure in East Asia and Oceania is 0.5 mg base/kg/day and elsewhere is 0.25 mg base/kg/day. Alternative treatments are under investigation. Expert commentary: Geographic heterogeneity in relapse patterns and chloroquine susceptibility of P. vivax, and G6PD deficiency epidemiology mean that radical treatment should be given much more than it is today. G6PD testing should be made widely available so primaquine can be given more safely.
登录
查看更多内容
影响因子：
6.4
作者：
Betuela, Inoni;Rosanas-Urgell, Anna;Mueller, Ivo
通讯作者：
Mueller, Ivo
DOI：
10.1590/s0037-86822001000400006
发表时间：
2001-07-01
影响因子：
2
作者：
Abdon, N P;Pinto, A Y;de Souza, J M
通讯作者：
de Souza, J M
影响因子：
2.3
作者：
Avula, Bharathi;Tekwani, Babu L.;Walker, Larry A.
通讯作者：
Walker, Larry A.
影响因子：
4.9
作者：
Amaratunga, Chanaki;Sreng, Sokunthea;Fairhurst, Rick M.
通讯作者：
Fairhurst, Rick M.
影响因子：
3.7
作者：
Boel, Machteld E.;Rijken, Marcus J.;Nosten, Francois H.
通讯作者：
Nosten, Francois H.